How New Diabetes Drugs Spread in Taiwanese Hospitals
Author Information
Author(s): Wen Yu-Wen, Huang Weng-Foung, Lee Yue-Chune, Kuo Ken N, Tsai Chia-Rung, Tsai Yi-Wen
Primary Institution: Chang Gung University
Hypothesis
The study investigates how thiazolidinediones (TZDs) diffuse in the healthcare market in Taiwan.
Conclusion
Medical centers began to prescribe TZDs earlier and at a faster pace compared to other hospitals.
Supporting Evidence
- Prior hospital-level pharmaceutical prescription concentration significantly deterred the adoption of TZDs.
- Adoption of TZDs was slower in district hospitals than in medical centers.
- Non-profit hospitals adopted TZDs faster than public hospitals.
Takeaway
This study looks at how quickly hospitals in Taiwan started using a new diabetes drug and how much they used it over time.
Methodology
The study analyzed monthly prescription data for TZDs from 580 hospitals in Taiwan using Cox proportional hazards model and quantile regressions.
Potential Biases
Potential biases may arise from the exclusion of clinics and hospitals with low prescription volumes.
Limitations
The study lacks information on the margin between reimbursed price and pharmaceutical procurement cost, which may affect the findings.
Participant Demographics
The study included 580 hospitals treating patients with Type 2 diabetes in Taiwan, categorized by accreditation level and ownership type.
Statistical Information
P-Value
0.0000
Confidence Interval
95% CI = 0.01 to 0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website